Vericel Announces Appointment of Jonathan Hopper as Chief Medical Officer
August 20 2018 - 8:00AM
Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell
therapies for the sports medicine and severe burn care markets,
today announced the appointment of Jonathan Hopper as Chief Medical
Officer.
Dr. Hopper formerly served as Senior Medical Director,
Orthopedic Clinical Development for Ferring Pharmaceuticals, where
he was responsible for establishing and executing the company’s
strategy for Orthopedic clinical development. Prior to
joining Ferring Pharmaceuticals, he served in a number of senior
medical roles including Vice President, Global Medical Director for
Stryker Corporation. Dr. Hopper also has significant medical
device regulatory experience having served as a Senior Medical
Officer for the UK Medicines and Healthcare products Regulatory
Agency. Dr. Hopper graduated with a M.B. Ch.B. from
Birmingham University Medical School UK, is a Fellow of the Royal
College of Surgeons, Edinburgh, and attained an M.B.A. at Keele
University UK.
"Jon’s experience and expertise in orthopedics, wound care, and
combination biologic device products are an ideal fit with
Vericel’s current business and strategic focus,” said Nick
Colangelo, president and chief executive officer of Vericel.
"Jon will play a key role in the execution of our life cycle
management initiatives as well as our efforts to expand our product
portfolio by accessing assets complementary to our existing
business.”
About Vericel CorporationVericel is a leader in
advanced cell therapies for the sports medicine and severe burn
care markets. The company markets two cell therapy products
in the United States. MACI® (autologous cultured chondrocytes
on porcine collagen membrane) is an autologous cellularized
scaffold product indicated for the repair of symptomatic, single or
multiple full-thickness cartilage defects of the knee with or
without bone involvement in adults. Epicel® (cultured
epidermal autografts) is a permanent skin replacement for the
treatment of patients with deep dermal or full thickness burns
greater than or equal to 30% of total body surface area. For
more information, please visit the company's website at
www.vcel.com.
Epicel® and MACI® are registered trademarks of Vericel
Corporation. © 2018 Vericel Corporation. All rights reserved.
This document contains forward-looking statements, including,
without limitation, statements concerning anticipated progress,
objectives and expectations regarding our efforts to expand our
portfolio, the commercial potential of our products and growth in
revenues, intended product development, and objectives and
expectations regarding our company described herein, all of which
involve certain risks and uncertainties. These statements are
often, but are not always, made through the use of words or phrases
such as "anticipates," "intends," "estimates," "plans," "expects,"
"we believe," "we intend," and similar words or phrases, or future
or conditional verbs such as "will," "would," "should,"
"potential," "could," "may," or similar expressions. Actual results
may differ significantly from the expectations contained in the
forward-looking statements. Among the factors that may result in
differences are the inherent uncertainties associated with business
development activities, competitive developments, estimating the
commercial growth potential of our products and product candidates
and growth in revenues and improvement in costs, market demand for
our products, and our ability to supply or meet customer demand for
our products. These and other significant factors are discussed in
greater detail in Vericel's Annual Report on Form 10-K for the year
ended December 31, 2017, filed with the Securities and Exchange
Commission ("SEC") on March 5, 2018, Quarterly Reports on Form 10-Q
and other filings with the SEC. These forward-looking statements
reflect management's current views and Vericel does not undertake
to update any of these forward-looking statements to reflect a
change in its views or events or circumstances that occur after the
date of this release except as required by law.
(vcel-corp)
Global Media Contacts:David SchullRusso
Partners LLCDavid.schull@russopartnersllc.com+1 212-845-4271
(office)+1 858-717-2310 (mobile)
Karen ChaseRusso Partners LLCKaren.chase@russopartnersllc.com+1
646-942-5627 (office)+1 917-547-0434 (mobile)
Investor Contacts: Chad RubinSolebury
Troutcrubin@troutgroup.com+1 (646) 378-2947
Lee SternSolebury Troutlstern@troutgroup.com+1 (646)
378-2922
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Apr 2023 to Apr 2024